[Therapy of bronchopulmonary infection in smokers].
The efficacy and safety of Cifran OD, a new dosage form of ciprofloxacin with prolonged action were studied in the treatment of patients with bronchopulmonary infection (n=23). The drug was used orally in a dose of 1 g once a day. The patients were divided into 2 groups: group 1 included patients with aggravation of chronic bronchitis and group 2 included patients with bacterial pneumonia. The recovery was stated in 77.7% of the patients in group 1, the other 26.3% of the patients showed clinical improvement. In the patients with pneumonia (group 2) the recovery was recorded in 100% of the cases. No significant side effects were observed.